

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sinohealth Holdings Limited

中康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 2361)

RESIGNATION AND APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE BOARD COMMITTEE

The board (the “**Board**”) of directors (the “**Director(s)**”) of Sinohealth Holdings Limited (the “**Company**”) announces that:

1. Ms. Du Yilin (“**Ms. Du**”) has tendered her resignation as an independent non-executive Director with effect from 3 December 2025; and
2. Ms. Chui Hoi Yam (徐海音) (alias: 徐海瑛, former name: 徐海英) (“**Ms. Chui**”) has been appointed as an independent non-executive Director with effect from 3 December 2025.

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board announces that Ms. Du has tendered her resignation as independent non-executive Director, and will cease to act as a member of the audit committee (the “**Audit Committee**”), nomination committee (the “**Nomination Committee**”) and remuneration committee (the “**Remuneration Committee**”) of the Board with effect from 3 December 2025, in order to devote more time to her personal commitments.

Ms. Du has confirmed that she has no disagreement with the Board and is not aware of any matters in connection with her resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the shareholders of the Company (the “**Shareholders**”).

The Board would like to take this opportunity to express its gratitude and appreciation to Ms. Du for her valuable contribution to the Company during her tenure of office.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board also announces that Ms. Chui has been appointed as an independent non-executive Director, and a member of the Audit Committee, the Nomination Committee and the Remuneration Committee with effect from 3 December 2025.

The biographical details of Ms. Chui are set out as follows:

Ms. Chui Hoi Yam (徐海音) (alias: 徐海瑛, former name: 徐海英), aged 58. Ms. Chui was appointed as an independent non-executive director of Abbisko Cayman Limited, a company listed on the Main Board of the Stock Exchange (stock code: 2256), on 28 February 2025; an independent non-executive director of Everest Medicines Limited, a company listed on the Main Board of the Stock Exchange (stock code: 1952), on 19 January 2023; and an independent non-executive director of TransThera Sciences (Nanjing), Inc., a company listed on the Stock Exchange (stock code: 2617), on 17 October 2022. She was an executive director of China Biotech Services Holdings Limited, a company listed on the GEM of the Stock Exchange (stock code: 8037), from December 2022 to June 2023, and was redesignated as a non-executive director from 30 June 2023 to 13 June 2024. Ms. Chui was the president of Harbin Pharmaceutical Group Co., Ltd. (哈藥集團股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 600664), from March 2019 to May 2022 and a director of Harbin Pharmaceutical from January 2021 to May 2022, where she was responsible for the overall business operation. Ms. Chui has also worked in China Hewlett-Packard Co., Ltd. (中國惠普有限公司) and Novartis International. Ms. Chui received her bachelor's degree in Economic Administration and master's degree in Finance from Peking University, the People's Republic of China in July 1990 and July 2001, respectively.

The Company entered into a service agreement with Ms. Chui for a term of three years commencing from 3 December 2025. Ms. Chui will hold office until the next annual general meeting of the Company and shall then be eligible for re-election in accordance with the articles of association of the Company. Ms. Chui will be entitled to a Director's fee of RMB96,000 per year, which is determined with reference to her duties and responsibilities within the Company, the Company's performance and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Ms. Chui has confirmed that she does not (i) hold any directorship in any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) have any relationship with any Director, senior management or substantial or controlling shareholders of the Company; (iii) hold any position in the Company or other members of the Group; and (iv) have any interest in any shares of the Company (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)).

Ms. Chui has also confirmed (a) her independence as regards to each of the factors contained in Rules 3.13(1) to (8) of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**"); (b) that she had no past or present financial or other interest in the business of the Group or any connection with any core connected persons (as defined in the Listing Rules) of the Company; and (c) that there are no other factors that may affect her independence at the time of her appointment.

Save as disclosed above, there is no other matter in relation to Ms. Chui's appointment that is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules, nor is there any other matter that needs to be brought to the attention of the Shareholders.

The Board would like to extend a warm welcome to Ms. Chui in joining the Board.

CHANGES IN COMPOSITIONS OF THE BOARD COMMITTEES

Following the resignation of Ms. Du as an independent non-executive Director, Ms. Du ceased to be:

- i. a member of the Audit Committee;
- ii. a member of the Nomination Committee; and
- iii. a member of the Remuneration Committee.

Following the appointment of Ms. Chui as an independent non-executive Director, Ms. Chui was appointed to join the following Board committees as:

- i. a member of the Audit Committee;
- ii. a member of the Nomination Committee; and
- iii. a member of the Remuneration Committee.

By order of the Board
Sinohealth Holdings Limited
Wu Yushu
Chairman

Hong Kong, 3 December 2025

As at the date of this announcement, the executive Directors are Mr. Wu Yushu and Ms. Wang Lifang, the non-executive Director is Mr. Fu Haitao, and the independent non-executive Directors are Ms. Wang Danzhou, Ms. Chui Hoi Yam and Mr. Wei Bin.